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Abstract: PURPOSE Desmoids are locally infiltrative, nonmalignant soft tissue tumors. Surgery, ra-
diation therapy, and chemotherapy have been the mainstay of treatment, but relapse is common and
side effects can result in significant morbidity. MR-HIFU is increasingly recognized as an alternative
treatment modality. We assessed the success rate of MR-HIFU for the treatment of extra-abdominal
desmoids at our institute. MATERIALS AND METHODS Five patients with relapsing desmoid tu-
mors (three males, two females; age range 40-79 years) were treated using the Sonalleve system in an
outpatient setting without general anesthesia. Changes in total tumor volumes were measured with a
tumor tracking software. Adverse events were documented. RESULTS MR-HIFU was successful in all
patients without severe side effects. Follow up ranged from 13 to 60 months. Three patients required
more than one treatment session. In 3 patients with small lesions (mean = 9.7 mL), complete ablation
was achieved with no evidence of viable tumor on follow up MRI at an average of 35.7 months, while in
two patients with larger lesions (mean = 46 mL) the targeted tumor volumes decreased by 73% at 14
months. Skin injuries comprised first- and second-degree burns and were observed with short distance
to skin (mean = 0.9 cm) and proximity to bone (i.e. ribs). Skin burns healed within weeks with topical
treatment. CONCLUSION MR-HIFU shows good mid-term result for extra-abdominal desmoids with
complete response for small lesions and stabilization of larger lesions. MR-HIFU for desmoids can be
performed under regional anesthesia/sedation as outpatients.
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Mid-term results of MR-guided high-intensity focused ultrasound treatment for
relapsing superficial desmoids
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ABSTRACT
Purpose: Desmoids are locally infiltrative, nonmalignant soft tissue tumors. Surgery, radiation therapy,
and chemotherapy have been the mainstay of treatment, but relapse is common and side effects can
result in significant morbidity. MR-HIFU is increasingly recognized as an alternative treatment modality.
We assessed the success rate of MR-HIFU for the treatment of extra-abdominal desmoids at
our institute.
Materials and methods: Five patients with relapsing desmoid tumors (three males, two females; age
range 40–79 years) were treated using the Sonalleve system in an outpatient setting without general
anesthesia. Changes in total tumor volumes were measured with a tumor tracking software. Adverse
events were documented.
Results: MR-HIFU was successful in all patients without severe side effects. Follow up ranged from 13
to 60months. Three patients required more than one treatment session. In 3 patients with small
lesions (mean ¼ 9.7mL), complete ablation was achieved with no evidence of viable tumor on follow
up MRI at an average of 35.7months, while in two patients with larger lesions (mean ¼ 46mL) the tar-
geted tumor volumes decreased by 73% at 14months. Skin injuries comprised first- and second-
degree burns and were observed with short distance to skin (mean ¼ 0.9 cm) and proximity to bone
(i.e. ribs). Skin burns healed within weeks with topical treatment.
Conclusion: MR-HIFU shows good mid-term result for extra-abdominal desmoids with complete
response for small lesions and stabilization of larger lesions. MR-HIFU for desmoids can be performed
under regional anesthesia/sedation as outpatients.
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Desmoid tumors (also known as aggressive fibromatosis) are
rare locally infiltrative soft tissue tumors arising from musculoa-
poneurotic tissues with no known potential for metastasis.
Tumor-related destruction of vital structures leads to morbidity
and in case of organ destruction to mortality. Although they
can occur at any age, most desmoids arise in individuals
between the age of 15 and 60 years [1]. Based on location,
desmoids are divided into extra-abdominal (trunk and extrem-
ities), also called superficial desmoids, and intra-abdominal
tumors. Risk factors include prior trauma or surgery and preg-
nancy. In 5–15% of patients there is an association with familial
adenomatous polyposis (FAP) called Gardner syndrome. These
patients tend to develop abdominal desmoids (intra-abdominal
or abdominal wall) [2,3]. With the increasing use of prophylac-
tic colectomy, desmoids are now a more important cause of
morbidity and mortality in this patient group [4].
The treatment of desmoids, including surgery, radiation
und medical treatments, has been historically frustrating
because there was no single best option with definitive
success. Multiple studies suggest that close observation is a
viable option for asymptomatic patients if no vital structures
are endangered [5–7], therefore, a watch and wait strategy is
initially advocated. However, treatment may be pursued in
patients with progressive disease, symptoms, risk of involve-
ment of adjacent structures or cosmetic concerns. Treatment
options include surgery with or without radiation therapy
and systemic medical therapy. Surgery carries a high risk of
local recurrence even after complete resection with negative
margins [8,9]. Radiation therapy in the long term carries risks
of fibrosis and strictures, and of secondary malignancy, a par-
ticular concern in younger patients. In addition, radiation
therapy seems to be less effective in children [10].
Recently, local therapeutic options like percutaneous
cryoablation, radiofrequency ablation, and high-intensity
focused ultrasound (HIFU) have been described [11–13].
MR-HIFU is increasingly being recognized as an alternative
treatment modality for prostate cancer, uterine fibroids, bone
tumors, breast tumors, and even neurological disorders of
the brain [14]. In addition, there have been applications for
visceral organ tumors, e.g. the liver [15].
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In 2011, Wang et al. were the first to describe ultrasound-
guided HIFU therapy as a treatment option for extra-abdom-
inal desmoid tumors with good success [16]. A few years
later Avedian et al. introduced HIFU with MR-guidance and
thermal mapping [17]. In addition to other advantages, MR-
guidance allows immediate acquisition of post-interventional
images with contrast to assess residual viability of tumor and
thus treatment success.
Interestingly, there are only few reports on this relatively
novel treatment option of MR-HIFU in patients with des-
moids. The purpose of this study was to assess the success
rate of MR-HIFU for the treatment of extra-abdominal des-
moid tumors at our institute.
Materials and methods
We retrospectively analyzed patients referred for MR-HIFU
treatment at our institute between the years 2011 and 2017
with histopathologically proven desmoid tumor. In total, five
patients with relapsing desmoid tumors (three males, two
females; age range 40–79 years) were treated and followed.
Patients had provided written informed consent to use their
data for research purposes before treatment. Additional insti-
tutional review board approval was not required for retro-
spective studies up to five patients. Treatments were
performed under analgosedation with propofol and regional
or local anesthesia, based on tumor location and patient
preference (see Table 1). Procedures were performed by a
single physician with 8 years of experience in MR-HIFU inter-
ventions. A Sonalleve MR-HIFU system with an in-Table 1.2-
MHz transducer (Profound Medical Corp, Mississauga,
Canada) was used with a 1.5-T MR system (Philips,
Amsterdam, Netherlands). Procedure planning was typically
done using a sagittal 3D T2w TSE Image (TR 1000ms, TE
130ms field of view AP 250mm FH 250mm RL 132mm,
bandwidth 832Hz). The size and the number of the sonica-
tions were adjusted to the size of the desmoid tumors. The
initial choice of sonication power was based on the tissue
temperature response to a low power test sonication, and
subsequently adjusted based on MR thermometry during
treatment. Overall the following parameter were used: fre-
quency 1.4MHz, 40–140W, and treatment or feedback cells
sized between 4mm and 16mm, corresponding to volumes
of 0.1–5.4ml. A tissue peak temperature of 60 C was tar-
geted. The whole tumor was targeted in one session with no
margins from the edge of the tumor. Post-contrast images
after treatment were used to assess the non-perfused tumor
areas and thus treatment effect (Figure 1). Patients were all
discharged home the same day with a prescription
for NSAIDs.
Clinical and imaging follow-up was performed after 3 and
6months and then every 12months. Changes in total tumor
volumes were measured with a tumor tracking software
(IntelliSpace V8.0, Philips, Amsterdam, Netherlands) on post-
contrast images. Patients with residual contrast enhancing
desmoid tissue were considered for re-treatment. Adverse
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additionally, burns were graded according to the American
Burn Association (ABA) in first, second, third, and
fourth degree.
Results
Two patients had desmoids located in the rectus abdominis
muscle, one in the deltoid muscle, one in the intercostal
muscles and one in the popliteal fossa (Table 1). All patients
had received prior treatment (surgery or radiation therapy)
with disease relapse. In the patient with a large desmoid in
the popliteal fossa, the deeper part of the desmoid could
not be treated by MR-HIFU because of encasement of neuro-
vascular structures. Three patients showed contrast enhanc-
ing nodules during follow-up, indicating insufficient thermal
ablation, and therefore required additional treatment ses-
sions (within 2 months, 10 months, and 3 years, respectively;
see Table 1). The number of sonications ranged from 4 to 17
and sonication duration from 20min to 123min, depending
on the tumor size. Average treatment temperature was
64.5 C (range 62–75). Follow-up periods range from 13
to 60months.
MR-HIFU was successful in all patients with good treat-
ment effect and without severe side effects. In three patients
with small desmoids (mean ¼ 9.7ml, range 3–23ml), com-
plete ablation was achieved with no evidence of viable
tumor on follow up MRI (Figure 2) at an average of
35.7months (range 20–60months), while in two patients
with larger lesions (mean¼ 46ml, range 22–70ml), targeted
tumor volumes decreased by 73% at 13 and 15months,
respectively. No patient required analgesia beyond NSAIDs.
Slight skin redness (first-degree burn) was noted in 2/5
patients while second-degree skin burn was observed in
another two patients and thought to correlate with distance
to skin (average 0.9 cm [0.5–1.5 cm]) as well as proximity to
bone (i.e. ribs). The patient without skin burn had a skin-
tumor distance of 2.5 cm. Skin burns were all less than 2 cm
in diameter and healed after a few weeks with topical
cream-based therapy.
Discussion
Desmoids are locally infiltrative tumors without potential for
metastasis and with a predilection for recurrence after surgi-
cal excision, making them a very attractive target for local
therapies. Our study adds to the evolving evidence that MR-
HIFU treatment of superficial desmoids is a viable treatment
option because of its favorable features, i.e. definitive thera-
peutic effect, repeatability, low adverse effects and no evi-
dence of triggering new lesions.
In this study, we used the volumetric MR-HIFU Sonalleve
system for treatment of patients, while previous studies
mostly used the ExAblate 2000 (InSightec, Haifa, Israel) HIFU
system, which uses a different ablation strategy. Volumetric
ablation allows controlled heating of a larger volume per
sonication by rapid spiral wise movement of the focal spot.
Additionally, thermal ablation is controlled utilizing feedback
cells that modify the sonication parameters and generate a
spatially controlled temperature profile at the treatment loca-
tion [18].
Our observed volume reduction is similar to previously
published studies that reported a volume decrease between
39% and 100% [16,17,19–22].
Since all MR-HIFU were performed without general anes-
thesia on an outpatient basis, repetition of the treatment
was well accepted by our patients.
HIFU can be performed with ultrasound or MR guidance.
The advantage of MR guidance is the thermal mapping
which allows visual feedback of the temperature within the
desmoid as well as in the near- and far-field enabling
Figure 1. (a) MRI (T1 FS SPIR sequence with contrast) of popliteal fossa before treatment. (b) Subtraction sequence with contrast directly post-HIFU. (c) Post-proc-
essing of lesion with tumor tracking tool. Note that due to (unfortunate) different angulation of MR-sequences pre- and post-contrast the bone is not in the same
plane as the tumor in the pre-contrast sequence.
540 A. NAJAFI ET AL.
adjustments to the sonication parameters. The dense (T2
hypointense) tissue of desmoids seem to be favorable for
HIFU therapy by absorbing sufficient energy with rather low
sonication energy if e.g. compared to fibroid treatment
(typically less than 100Watt were used). The precision of
MR-HIFU was studied by Avedian et al. using four cadaver
extremities and reported an ablation margin accuracy of
3–8mm [17], which matches our clinical experience. In add-
ition, the MR imaging allows post-treatment contrast
enhanced images which can delineate untreated desmoid tis-
sue. Careful evaluation of immediate post-treatment images
is important in order not to misinterpret the enhancing
hyperemic rim around the treatment area with residual des-
moid. It is advisable to use subtraction technique between
pre- and post-contrast T1 weighted images not only to
detect the enhancing areas better but also not to be con-
fused by potentially non enhancing T1 hyperintense areas.
MR-HIFU is a non-invasive alternative compared to surgery
or radiation therapy. The most feared complications of HIFU
therapy are neural injuries because of the thermal sensitivity
of neuronal tissue. In order to avoid neural damage, rigorous
planning is necessary and as in one of our cases certain
areas close to neural structures cannot be treated. The most
common complication is thermal injuries in the near field,
which cannot always be avoided due to the superficial pos-
ition of the desmoids. Two of our five patients suffered a
grade 2 skin burn of less than 2 cm diameter which healed
with topical treatment. Typically the risk of a skin burn
increases if the shortest distance between desmoid and skin
is less than 10mm or if there is proximity to bone as with
the ribs in one of our cases due to extensive reflection of
the ultrasound waves. One possible solution in such cases
would be to use an active cooling system to protect the skin
or to decrease the sonication power. We did not observe any
injuries in the far field, but there is a report of thermal inju-
ries in the far field especially after repeated sonications due
to greater tumor volume [21]. Since none of the factors
applied to our patients we did not take any dedicated pre-
cautions regarding possible far-field injuries.
Besides possible skin damage there is very little discom-
fort after MR-HIFU of desmoids. Post-procedural pain is
usually mild and readily treatable with non-steroidal anti-
inflammatory drugs (NSAIDs). In fact, patients with desmoid
related pain reported a decrease of their complaint after
HIFU therapy after a few weeks which has also been
described in the literature [21].
Our study is limited by sample size, retrospective design,
and lack of a randomized comparison with other treatment
options. The latter, however, is difficult because superficial
desmoids are rare and enrollment in a randomized compara-
tive study would be challenging because the morbidity of
radiation therapy and surgery is much higher than MR-HIFU.
In conclusion, MR-HIFU offers a non-invasive outpatient
treatment option for relapsing superficial desmoids after sur-
gery with promising midterm results. Because of its morbid-
ity MR-HIFU may also be considered as a primary treatment
option for superficial desmoids.
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